Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.
Avani Yenamandra, PharmD, BCOP
Advertisement
Articles by Avani Yenamandra, PharmD, BCOP
BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Second-line and later treatment options for small cell lung cancer are limited.
These combination therapies have demonstrated longer PFS with a tolerable AE profile.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
2
Therapeutic Cancer Vaccines: Are We There Yet?
3
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
4
FDA Approves Gazyva for Active Lupus Nephritis
5
